Ai Tumor Evolution Maps Market
AI Tumor Evolution Maps Market Forecasts to 2032 – Global Analysis By Cancer Type (Brain Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Pancreatic Cancer, Hematologic Malignancies, Rare & Pediatric Cancers and Other Cancer Types), Technology, Application, End User and By Geography
According to Stratistics MRC, the Global AI Tumor Evolution Maps Market is accounted for $196.03 million in 2025 and is expected to reach $1390.77 million by 2032 growing at a CAGR of 32.3% during the forecast period. Artificial Intelligence Tumor Evolution Maps are innovative systems designed to study how cancers develop, mutate, and react to different therapies over time. These maps process extensive genomic profiles, medical scans, and patient records to uncover the dynamic nature of tumor progression. By revealing how cancer cells adapt and acquire drug resistance, they assist researchers in forecasting clinical outcomes and tailoring personalized treatments. Unlike conventional approaches, AI-driven models merge diverse datasets, highlighting subtle interactions within tumor biology that might otherwise remain hidden. This cutting-edge methodology equips oncologists with deeper insights, enabling more accurate therapeutic decisions and offering improved prospects for cancer management.
According to the International Agency for Research on Cancer (IARC), The number of cancer-associated deaths is projected to increase from 7.6 million in 2008 to 13 million in 2030—a rise of approximately 72%.
Market Dynamics:
Driver:
Increasing cancer incidence
The global rise in cancer cases is significantly boosting the demand for AI Tumor Evolution Maps. With more patients being diagnosed, healthcare systems require sophisticated tools to track tumor growth, anticipate changes, and support individualized therapy decisions. AI-based maps allow clinicians to process extensive genomic and clinical datasets, enhancing care management. Increasing awareness of cancer risks and treatment options, along with the growth of various cancer types, further stimulates the adoption of these technologies. This situation drives investment in AI solutions that aid in early detection, precise treatment strategies, and improved patient survival, making them an essential part of modern oncology practices.
Restraint:
High implementation costs
The significant cost of implementing AI Tumor Evolution Maps is a major market restraint. Establishing and maintaining these systems requires heavy investment in computing hardware, software solutions, and skilled professionals. Smaller healthcare facilities often cannot bear these costs, limiting their access to AI-powered tumor mapping. Additional expenses related to software updates, data management, and integration with existing clinical workflows further compound the challenge. These financial barriers can slow market growth, restrict the entry of new competitors, and hinder adoption in developing regions. Despite the advantages of AI-driven tumor evolution tools, high implementation costs remain a critical factor preventing broader utilization across hospitals and clinics worldwide.
Opportunity:
Increasing demand for precision oncology
Rising interest in precision oncology offers strong growth potential for the AI Tumor Evolution Maps market. Both patients and healthcare providers are increasingly focused on personalized treatment approaches that consider individual tumor characteristics, genetic alterations, and therapy outcomes. AI-enabled tumor evolution platforms can analyze complex information, detect subtle patterns, and generate actionable recommendations for customized treatments. As precision medicine gains traction, the need for AI tools that support accurate prognosis, optimize therapy, and anticipate resistance is growing. Providers of AI-based tumor mapping solutions can capitalize on this demand to expand their market reach, improve patient care, and advance the implementation of targeted cancer therapies globally.
Threat:
Competition from traditional methods
Traditional cancer diagnostic and monitoring techniques present a threat to the AI Tumor Evolution Maps market. Traditional approaches such as biopsies, pathology examinations, and standard imaging techniques are well-established, reliable, and generally more affordable compared to AI-driven platforms. Healthcare providers may hesitate to implement new AI technologies due to concerns over accuracy, workflow integration, and training requirements. Resistance to adopting novel approaches can slow the market penetration of AI tumor evolution solutions, especially in resource-limited regions. Traditional methods also benefit from regulatory approval experience and extensive clinical validation. As a result, AI platforms face strong competition from conventional practices, which may limit adoption despite the potential for technological improvements.
Covid-19 Impact:
The COVID-19 pandemic had a notable effect on the AI Tumor Evolution Maps market. Many hospitals and research centers experienced disruptions in routine cancer care, including screenings, therapies, and clinical studies, leading to a temporary decline in demand for AI-based tumor mapping systems. Supply chain delays further hindered the deployment of necessary hardware and software. Conversely, the pandemic accelerated the integration of digital health solutions, telemedicine, and AI analytics, demonstrating the critical role of remote monitoring and predictive healthcare tools. Consequently, although short-term market growth slowed, COVID-19 underscored the importance of AI tumor evolution platforms in improving patient management, enhancing decision-making, and strengthening healthcare resilience.
The breast cancer segment is expected to be the largest during the forecast period
The breast cancer segment is expected to account for the largest market share during the forecast period. This dominance is due to the high prevalence of breast cancer worldwide and significant investments in AI research aimed at improving breast cancer care. AI-driven tools, including deep learning models and sophisticated imaging technologies, have significantly improved early detection, tailored treatment strategies, and ongoing monitoring of tumor development in breast cancer patients. As AI technologies continue to evolve, their application in breast cancer is expected to expand, reinforcing its leading role in the AI tumor mapping market.
The AI & health tech startups segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the AI & health tech startups segment is predicted to witness the highest growth rate. This growth is fueled by innovations in personalized medicine, where AI customizes treatments based on individual genetic information, lifestyle, and health history. Moreover, these startups are pioneering the integration of AI with genomics and clinical data, providing novel solutions that significantly improve the precision and effectiveness of cancer diagnostics and treatment strategies. Their adaptability and emphasis on advanced technologies establish them as key players in the rapidly advancing field of AI-powered oncology.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share. This leadership is driven by factors such as cutting-edge healthcare facilities, significant R&D investments, and a high incidence of cancer. Government support, including favorable regulations and initiatives, has further accelerated the adoption of AI technologies in oncology. The concentration of prominent technology firms and prestigious medical institutions in the region has created a robust ecosystem for the advancement and implementation of AI-based cancer diagnostic and treatment solutions.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. This surge is attributed to factors such as a rising prevalence of cancer, improvements in healthcare infrastructure, and an increased adoption of artificial intelligence in medical diagnostics. Nations like China, Japan, and India are making substantial investments in AI research and development, creating a favorable environment for market growth. Furthermore, partnerships between healthcare institutions and technology companies are facilitating the integration of AI solutions in oncology. These factors collectively position the APAC region as a key player in the global AI Tumor Evolution Maps market.
Key players in the market
Some of the key players in AI Tumor Evolution Maps Market include Azra AI, Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Median Technologies, PathAI, Paige, AstraZeneca, CancerIQ, X-ZELL, MNM Bioscience, Biotome, Immunai, OncoHost, Tempus and 1Cell.Ai.
Key Developments:
In August 2025, GE HealthCare and Gentuity LLC plan to collaborate on commercial activities to enhance the availability, adoption and functionality of highly complementary imaging solutions for interventional cardiology. The collaboration is intended to enhance the availability, adoption and functionality of highly complementary imaging solutions for interventional cardiology.
In April 2025, Azra AI and Elekta announce partnership to enhance cancer registry operations with AI-powered automation. This partnership combines Azra AI’s real-time patient identification and workflow automation with Elekta’s next-generation cancer registry software, Elekta ONE Registry Informatics*. The combined technologies will enable cancer registry teams to automate cancer casefinding, streamline data ingestion, increase reporting accuracy, and ensure compliance with national and international standards.
In January 2025, Siemens Healthineers has entered into a technology licensing agreement with Kromek Group Plc to enable the in-house production of cadmium zinc telluride (CZT) material for gamma ray detectors used in single-photon emission computed tomography (SPECT) systems. Under the terms of the agreement, Siemens Healthineers will license Kromek’s technology to produce CZT, which will extend its research, development, and manufacturing capabilities to allow for a potential future line of gamma ray detectors for multi-modal SPECT systems.
Cancer Types Covered:
• Brain Cancer
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Pancreatic Cancer
• Hematologic Malignancies
• Rare & Pediatric Cancers
• Other Cancer Types
Technologies Covered:
• Imaging-Based Mapping (MRI, CT, PET)
• Genomic and Transcriptomic Mapping
• AI-Powered Predictive Modeling
• Multi-Omics Integration Platforms
• Spatial Transcriptomics
• Digital Twin Modeling
• Federated Learning & Privacy-Preserving AI
Applications Covered:
• Diagnosis and Early Detection
• Prognosis and Risk Assessment
• Treatment Planning
• Drug Development and Clinical Trials
• Tumor Monitoring and Recurrence Prediction
• Biomarker Discovery
• Patient Stratification for Immunotherapy
End Users Covered:
• Hospitals and Clinics
• Research Institutes
• Pharmaceutical & Biotechnology Companies
• Academic Institutions
• Diagnostic Laboratories
• AI & Health Tech Startups
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global AI Tumor Evolution Maps Market, By Cancer Type
5.1 Introduction
5.2 Brain Cancer
5.3 Lung Cancer
5.4 Breast Cancer
5.5 Colorectal Cancer
5.6 Prostate Cancer
5.7 Pancreatic Cancer
5.8 Hematologic Malignancies
5.9 Rare & Pediatric Cancers
5.10 Other Cancer Types
6 Global AI Tumor Evolution Maps Market, By Technology
6.1 Introduction
6.2 Imaging-Based Mapping (MRI, CT, PET)
6.3 Genomic and Transcriptomic Mapping
6.4 AI-Powered Predictive Modeling
6.5 Multi-Omics Integration Platforms
6.6 Spatial Transcriptomics
6.7 Digital Twin Modeling
6.8 Federated Learning & Privacy-Preserving AI
7 Global AI Tumor Evolution Maps Market, By Application
7.1 Introduction
7.2 Diagnosis and Early Detection
7.3 Prognosis and Risk Assessment
7.4 Treatment Planning
7.5 Drug Development and Clinical Trials
7.6 Tumor Monitoring and Recurrence Prediction
7.7 Biomarker Discovery
7.8 Patient Stratification for Immunotherapy
8 Global AI Tumor Evolution Maps Market, By End User
8.1 Introduction
8.2 Hospitals and Clinics
8.3 Research Institutes
8.4 Pharmaceutical & Biotechnology Companies
8.5 Academic Institutions
8.6 Diagnostic Laboratories
8.7 AI & Health Tech Startups
9 Global AI Tumor Evolution Maps Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Azra AI
11.2 Siemens Healthineers AG
11.3 GE HealthCare
11.4 NVIDIA Corporation
11.5 Median Technologies
11.6 PathAI
11.7 Paige
11.8 AstraZeneca
11.9 CancerIQ
11.10 X-ZELL
11.11 MNM Bioscience
11.12 Biotome
11.13 Immunai
11.14 OncoHost
11.15 Tempus
11.16 1Cell.Ai
List of Tables
1 Global AI Tumor Evolution Maps Market Outlook, By Region (2024-2032) ($MN)
2 Global AI Tumor Evolution Maps Market Outlook, By Cancer Type (2024-2032) ($MN)
3 Global AI Tumor Evolution Maps Market Outlook, By Brain Cancer (2024-2032) ($MN)
4 Global AI Tumor Evolution Maps Market Outlook, By Lung Cancer (2024-2032) ($MN)
5 Global AI Tumor Evolution Maps Market Outlook, By Breast Cancer (2024-2032) ($MN)
6 Global AI Tumor Evolution Maps Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
7 Global AI Tumor Evolution Maps Market Outlook, By Prostate Cancer (2024-2032) ($MN)
8 Global AI Tumor Evolution Maps Market Outlook, By Pancreatic Cancer (2024-2032) ($MN)
9 Global AI Tumor Evolution Maps Market Outlook, By Hematologic Malignancies (2024-2032) ($MN)
10 Global AI Tumor Evolution Maps Market Outlook, By Rare & Pediatric Cancers (2024-2032) ($MN)
11 Global AI Tumor Evolution Maps Market Outlook, By Other Cancer Types (2024-2032) ($MN)
12 Global AI Tumor Evolution Maps Market Outlook, By Technology (2024-2032) ($MN)
13 Global AI Tumor Evolution Maps Market Outlook, By Imaging-Based Mapping (MRI, CT, PET) (2024-2032) ($MN)
14 Global AI Tumor Evolution Maps Market Outlook, By Genomic and Transcriptomic Mapping (2024-2032) ($MN)
15 Global AI Tumor Evolution Maps Market Outlook, By AI-Powered Predictive Modeling (2024-2032) ($MN)
16 Global AI Tumor Evolution Maps Market Outlook, By Multi-Omics Integration Platforms (2024-2032) ($MN)
17 Global AI Tumor Evolution Maps Market Outlook, By Spatial Transcriptomics (2024-2032) ($MN)
18 Global AI Tumor Evolution Maps Market Outlook, By Digital Twin Modeling (2024-2032) ($MN)
19 Global AI Tumor Evolution Maps Market Outlook, By Federated Learning & Privacy-Preserving AI (2024-2032) ($MN)
20 Global AI Tumor Evolution Maps Market Outlook, By Application (2024-2032) ($MN)
21 Global AI Tumor Evolution Maps Market Outlook, By Diagnosis and Early Detection (2024-2032) ($MN)
22 Global AI Tumor Evolution Maps Market Outlook, By Prognosis and Risk Assessment (2024-2032) ($MN)
23 Global AI Tumor Evolution Maps Market Outlook, By Treatment Planning (2024-2032) ($MN)
24 Global AI Tumor Evolution Maps Market Outlook, By Drug Development and Clinical Trials (2024-2032) ($MN)
25 Global AI Tumor Evolution Maps Market Outlook, By Tumor Monitoring and Recurrence Prediction (2024-2032) ($MN)
26 Global AI Tumor Evolution Maps Market Outlook, By Biomarker Discovery (2024-2032) ($MN)
27 Global AI Tumor Evolution Maps Market Outlook, By Patient Stratification for Immunotherapy (2024-2032) ($MN)
28 Global AI Tumor Evolution Maps Market Outlook, By End User (2024-2032) ($MN)
29 Global AI Tumor Evolution Maps Market Outlook, By Hospitals and Clinics (2024-2032) ($MN)
30 Global AI Tumor Evolution Maps Market Outlook, By Research Institutes (2024-2032) ($MN)
31 Global AI Tumor Evolution Maps Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
32 Global AI Tumor Evolution Maps Market Outlook, By Academic Institutions (2024-2032) ($MN)
33 Global AI Tumor Evolution Maps Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
34 Global AI Tumor Evolution Maps Market Outlook, By AI & Health Tech Startups (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
